SCHEMBL1860966

SCHEMBL1860966

O=C(OC1COC(c2ccccc2)OC1)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.46
▸ MAPT P10636 3/20 0.41
▸ GAA P10253 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ LMNA P02545 2/20 0.40
▸ RECQL P46063 1/20 0.40
▸ P2RX7 Q99572 1/20 0.40
▸ CYP2C19 P33261 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2151170 0.78 MEN1 (0.42) MAPK1ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL17785114 0.78 MEN1 (0.44) MAPTMAPK1ALDH1A1CYP2C19MEN1
SCHEMBL19328433 0.78 MEN1 (0.44) MAPTALDH1A1CYP2C19SMN1; SMN2MEN1
SCHEMBL12199520 0.75 SLC18A3 (0.43) ALDH1A1CYP2C19MEN1KMT2APOLB
SCHEMBL29177227 0.75 MEN1 (0.46) MAPTMAPK1ALDH1A1LMNACYP2C19
SCHEMBL31006992 0.75 MAPK1 (0.41) MAPTMAPK1ALDH1A1CYP2C19SMN1; SMN2
SCHEMBL14038138 0.74 MEN1 (0.41) MAPTGAACYP2C19MEN1KMT2A
SCHEMBL13278373 0.74 MEN1 (0.41) MAPTGAACYP2C19MEN1KMT2A
SCHEMBL10833008 0.73 BCHE (0.45) MAPTMAPK1ALDH1A1CYP2C19MEN1
SCHEMBL12199634 0.73 MEN1 (0.40) ALDH1A1CYP2C19MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1935879-B1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-05-11 — — EP disclosed
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 — — US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 — — US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 — — US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF KDM4E 4338/4885MAPT 4856/4885GAA 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback